Previous Close | 8.12 |
Open | 8.28 |
Bid | 8.13 x 1000 |
Ask | 8.45 x 1100 |
Day's Range | 8.12 - 8.60 |
52 Week Range | 5.26 - 75.20 |
Volume | |
Avg. Volume | 1,517,313 |
Market Cap | 462.943M |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Ginkgo Bioworks Holdings ( NYSE:DNA ) Second Quarter 2024 Results Key Financial Results Revenue: US$56.2m (down 30...
There's been a notable change in appetite for Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) shares in the week since its...
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.